Pharmaceutical giant GlaxoSmithKline’s massive health care fraud settlement made the list, too.
The 94 federal prosecuting offices across the country returned more than six times their operating budgets to the U.S. Treasury through collection of fines and penalties.
Officials noted a focus on financial fraud and health care fraud.
Bradley Birkenfeld’s lawyers say they believe it is the largest whistleblower award ever, though the IRS won’t confirm.
Just Anti-Corruption has learned that the British anti-fraud agency is prepared to move against the Eurasian Natural Resources Corporation, in headlines in Britain over corruption allegations. But it has not pulled the trigger.
The Great Britain-based drugmaker admitted to introducing misbranded drugs and failing to report safety data.
Is the biggest corruption vs. anti-corruption drama a long, long way from the Rio Grande?
Lawyers in several high-profile prosecutions last year explained their strategies at the American Bar Association’s white collar crime meeting in Miami last week.
Do the terms “white collar” and “blue collar” apply in the world of FCPA enforcement?
In FY 2010 and 2011, corporate fraud yielded $2.4 billion in restitution and $16.1 million in fines.
The agencies said they returned $4.1 billion to the U.S. taxpayers in fiscal 2011.
Charles Grassley — the lawmaker most closely associated with the False Claims Act and whistleblower protections — was invited to the event but did not attend. Sen. Patrick Leahy called the False Claims Act a “real success story in government.”
The Justice Department secured more than $3 billion in settlements and judgments in civil cases involving fraud against the government in the fiscal year ending Sept. 30, 2011, Tony West, Assistant Attorney General for the Civil Division, announced today.
Marc Smolonsky, associate deputy secretary at the Department of Health and Human Services, was among the panelists on Capitol Hill for the Main Justice forum: “What’s Next? Strategies for Improving Compliance with Fraud and Abuse Laws.”
The Justice Department and the Securities and Exchange Commission have been examining since 2004 whether the company violated the Foreign Corrupt Practices Act.
The company has previously disclosed that the SEC and DOJ are investigating it for potential violations of the FCPA.
Lauren Stevens was indicted twice in connection with the company’s response to an off-label marketing investigation. A federal judge threw the case out in May.
The pharmaceutical titan’s settlement marks the biggest ever in the United States over drug marketing.
What does the hiring of Reid Weingarten mean?
U.S. Attorney Rod J. Rosenstein signaled his reservations by withholding his signature.
The acquittal of Lauren Stevens of GlaxoSmithKline was not a proud moment for the department.
The plight of Lauren Stevens has been closely followed by the legal community.
The DOJ’s Criminal Fraud Section and the SEC are investigating at least five other major pharmaceutical companies: GlaxoSmithKline PLC; Baxter International Inc.; Eli Lilly & Co.; Bristol-Myers Squibb Co.; and Merck & Co.
With each new wrinkle the plight of a former GlaxoSmithKline lawyer stirs debate.
The DOJ shows no sign of tiring in its pursuit of Lauren Stevens, accused of misleading regulators.
The plight of GlaxoSmithKline’s ex-counsel continues to draw comment.
A judge delivers a setback for prosecutors in the closely watched case of Lauren Stevens.
Be sure you know which side “your” lawyer is on.
The drug maker has also fallen under the gaze of a separate, industry-wide probe into potential FCPA violations in the pharmaceutical industry currently being conducted by the SEC and the Justice Department.
The list is reasonably current as of Jan. 4, 2010.
"Are you saying there was no paper trail here?" - Rep. Tom Marino (R-Pa.) to AG Eric Holder about his undocumented recusal in the Associated Press leak probe.